Company believes its oral HAE prophylaxis will gradually reach the billion-dollar sales threshold, with about 80% of revenue coming from the US market.

Having looked at four prominent drug candidates which are expecting important top-line data this quarter, with the help of Biomedtracker's Q2 Outlook Report, we take a look at four other assets that could soon break into the US market, from infectious diseases to diabetes.

Takeda pursues RNA-targeting R&D with Evotec and Anima, looks into liver disease with Genevant. Plus deals involving Kyowa Kirin/Twist, Bright Peak/Ajinimoto & Torii/Verrica.

A new batch of marketing authorizations in Japan includes new therapies for high-need cancer indications and rare diseases, and the first nod worldwide for a novel lysosomal disorder treatment that can address serious CNS symptoms.